Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Debt Repayments (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Debt Repayments over the past 16 years, most recently at $145.1 million for Q2 2025.

  • Quarterly results put Long-Term Debt Repayments at $145.1 million for Q2 2025, down 0.8% from a year ago — trailing twelve months through May 2025 was $145.8 million (down 0.64% YoY), and the annual figure for FY2025 was $145.8 million, down 0.64%.
  • Long-Term Debt Repayments for Q2 2025 was $145.1 million at Lifecore Biomedical, Inc. \De\, up from $313000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for LFCR hit a ceiling of $146.2 million in Q2 2024 and a floor of $27000.0 in Q3 2022.
  • Median Long-Term Debt Repayments over the past 5 years was $289000.0 (2024), compared with a mean of $35.1 million.
  • Biggest five-year swings in Long-Term Debt Repayments: crashed 99.93% in 2022 and later skyrocketed 344160.0% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Long-Term Debt Repayments stood at $38000.0 in 2021, then grew by 28.95% to $49000.0 in 2022, then surged by 293.88% to $193000.0 in 2023, then decreased by 20.73% to $153000.0 in 2024, then skyrocketed by 94709.8% to $145.1 million in 2025.
  • The last three reported values for Long-Term Debt Repayments were $145.1 million (Q2 2025), $313000.0 (Q1 2025), and $153000.0 (Q4 2024) per Business Quant data.